At Oxford Global, we believe in the power of networking, connection, and knowledge to drive meaningful progress in life sciences. With this vision at our core, we’re excited to highlight two upcoming flagship events from our NextGen Biomed series - Biologics US 2025 and Cell UK 2025 - designed to deliver tailored experiences that spark innovation, build community, and accelerate collaboration across the biotherapeutic and advanced therapy landscapes.
Returning this October, Biologics US 2025 will once again serve as a premier gathering for leading scientists, industry experts, and innovators advancing the next generation of biologic therapies. Held over two impactful days, the event offers attendees a unique opportunity to explore cutting-edge developments across proteins, antibodies, and antibody-drug conjugates (ADCs), while fostering valuable partnerships that drive discovery and development forward.
Structured around four content tracks and three core programmes - Proteins & Antibodies, ADC Discovery & Development, and a dedicated Start-Up Zone - the meeting delivers a comprehensive look at the technologies and strategies redefining biologics. Sessions will feature the latest in protein and antibody engineering, innovative bioanalytical approaches, and translational case studies, while the ADC programme explores advances in drug conjugate development, clinical application, and manufacturing scalability. Meanwhile, our Start-Up Zone will showcase emerging biotech companies with disruptive technologies, offering a platform for early innovation and partnership.
A key theme of this year’s event is the application of AI and machine learning in biologics R&D, with in-depth discussions on their role in drug discovery workflows, target identification, and process optimisation. Attendees will also benefit from content addressing CMC strategy, clinical translation, and regulatory frameworks.
Distinguished keynote speakers include Steve Turner, Chief Executive Officer of Pangio Biosystems and former Founding CEO of PacBio, and Ray Deshaies, Senior Vice President of Global Research at Amgen. Additional spotlight speakers from organisations including PRISM, AbbVie, 3T Bioscience, Merck Life Science, and Amgen will share insights into breakthrough projects and technologies.
Interactive elements, including a roundtable on antibody discovery and a panel discussion on Women in Drug Discovery & Development, will deepen engagement and encourage inclusive dialogue across the industry. Co-located with Drug Discovery & Formulation & Delivery US 2025, this event also offers access to cross-disciplinary content and a broader scientific network.
With over 500 attendees, more than 13 industry partners, and over 200 pre-arranged 1-to-1 meetings expected, Biologics US 2025 is designed to empower attendees with the knowledge and connections needed to transform scientific innovation into life-changing therapies.
Following in November, Cell UK 2025 is Oxford Global’s flagship event for the cell culture, bioprocessing, and advanced therapies community. With more than 1,000 participants expected from pharma, biotech, academia, and regulatory bodies, this event serves as a vital hub for collaboration across every stage of the cell and gene therapy value chain.
The 2025 agenda features 12 content tracks and is built around three primary programmes: Cell Culture & Bioprocessing, Advanced Therapy Development, and Cell & Gene Therapy Manufacturing, as well as a Start-Up and Innovation Track showcasing emerging biotech talent and platforms.
Highlights include deep dives into streamlining cell line development, advancing 3D culture technologies, and harnessing AI-driven automation. Attendees will also gain practical insights into regulatory frameworks, clinical translation, and commercialisation strategies for cell and gene therapies.
The event features world-renowned leaders including Bobby Gaspar (Co-Founder and CEO of Orchard Therapeutics) who will discuss the end-to-end development and commercialisation of HSC gene therapies, Professor Dame Molly Stevens (John Black Professor of Bionanoscience, University of Oxford) presenting on the role of AI and bioengineering in advancing therapeutic development, and Christof von Kalle (Director, BIH & Charité Clinical Study Center BIH Chair for Clinical and Translational Sciences) sharing an all stakeholder approach to cell & gene therapy. They will be joined by spotlight speakers from Adaptimmune, TreeFrog Therapeutics, INmune Bio, Spark Therapeutics, the MHRA, Legend Biotech and more.
Erin Harris, Chief Editor of Cell & Gene, will host the event and moderate an inspiring Women in Life Sciences panel discussion, highlighting leadership and inclusion in the sector. Interactive sessions will encourage participation across a wide range of topics, including AI in CGT development, cell line engineering innovations, patient-focused clinical trials, and global regulatory strategy.
The Start-Up Zone is a dynamic platform for emerging biotech pioneers, while more than 45 industry partners and 10+ hours of dedicated networking create invaluable opportunities for forging new collaborations and identifying future innovation hotspots.
Together, Biologics US 2025 and Cell UK 2025 represent Oxford Global’s NextGen Biomed brand - two world-class events built to equip attendees with actionable insights, strategic connections, and forward-looking perspectives in biologics, bioprocessing, and advanced therapy development.
Secure your place today and join the global community driving the next era of therapeutic innovation.